Cancer Research
5 articles
Pfizer lung cancer drug: 60% progression-free after five years
After five years, 60% of patients with a specific type of lung cancer treated with Pfizer's lorlatinib were still alive without their disease progressing, a dramatic finding compared to just 8% on the
Revolution Medicines' Experimental Pancreatic Cancer Drug Shows Promise
Revolution Medicines' experimental drug daraxonrasib doubled the median overall survival for patients with metastatic pancreatic cancer to 13.2 months in its pivotal Phase 3 trial.
BioNTech, Pfizer Share Bispecifics Data at ASCO
BioNTech's BNT142 achieved 7 RECIST 1.
Bristol Myers Squibb shows strong multiple myeloma data
In a significant development for multiple myeloma patients, Bristol Myers Squibb's mezigdomide triplet demonstrated a median progression-free survival of 18 months, more than doubling the 8.
Microbiota Induces T Cell Plasticity for Tumor Control
In a groundbreaking study, researchers found that the presence of a specific gut bacterium, Segmented Filamentous Bacteria (SFB), dramatically boosted the anti-tumor effects of PD-1 immunotherapy in m